13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
|
Name |
WKN |
Börse |
Kurs |
Datum/Zeit |
Diff. |
Diff. % |
Geld |
Brief |
Erster |
Schluss |
|
SANOFI SA INHABER EO 2 |
920657 |
Xetra |
88,690 |
30.05.24 17:35:37 |
+0,670 |
+0,76% |
0,000 |
0,000 |
88,230 |
88,020 |
|
Regeneron Pharmaceuticals |
881535 |
NASDAQ |
962,845 |
30.05.24 20:09:05 |
-3,645 |
-0,38% |
962,050 |
963,350 |
965,580 |
966,490 |